CuraGen (CRGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CuraGen (CRGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: fut_trade who wrote (17)	4/14/1998 10:39:00 AM
From: fut_trade	Read Replies (1) of 478

Tuesday April 14, 10:11 am Eastern Time RESEARCH ALERT - CuraGen started NEW YORK, April 14 (Reuters) - Lehman Brothers said analyst Matthew Murray initiated coverage of CuraGen Corp. with a ''venture outperform'' rating. -- said in report company's ''ability to both discover genes and identify the pathway involved should be appealing to pharmaceutical companies as it offers 'one-stop shopping' for drug discovery.'' -- set 12-month price target of $21 on the shares, which were up 5/8 at 12-1/2.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next